公开(公告)号：US20220185785A1

公开(公告)日：2022-06-16

申请号：US17603260

申请日：2020-04-13

Applicant: TONIX PHARMACEUTICALS HOLDING CORP

Inventor： Darryl RIDEOUT ,  Seth LEDERMAN

IPC: C07D257/04 ,  C07D403/12 ,  C07D403/10 ,  C07D285/135 ,  C07D275/06 ,  C07D213/81 ,  C07D249/06 ,  C07D307/68 ,  C07C237/42 ,  C07C311/51 ,  C07C317/44 ,  C07D333/38 ,  C07D231/56 ,  C07D211/34 ,  C07D213/52 ,  C07C233/80 ,  C07C259/10 ,  C07D213/75 ,  C07D237/20 ,  C07D401/14 ,  C07D487/04

Abstract: Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L. The compounds are useful for treating, ameliorating or preventing an autoimmune disease, inflammatory disease, or other immune-related disease in a patient in need of treatment.